Sutro Biopharma (NASDAQ:STRO) Given Neutral Rating at HC Wainwright

Sutro Biopharma (NASDAQ:STRO)‘s stock had its “neutral” rating reiterated by research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $2.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 123.02% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Bank of America lowered shares of Sutro Biopharma from a “buy” rating to an “underperform” rating and decreased their price objective for the company from $11.00 to $1.00 in a report on Friday, March 14th. Piper Sandler set a $2.00 price target on shares of Sutro Biopharma in a research note on Friday, March 14th. Citizens Jmp cut Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, March 14th. Finally, Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $2.00 in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.63.

Sutro Biopharma Stock Performance

Shares of NASDAQ STRO opened at $0.90 on Tuesday. Sutro Biopharma has a fifty-two week low of $0.52 and a fifty-two week high of $5.17. The company has a market cap of $75.66 million, a price-to-earnings ratio of -0.56 and a beta of 1.70. The business’s 50 day moving average price is $0.97 and its 200-day moving average price is $1.99.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing the consensus estimate of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The business had revenue of $14.00 million during the quarter, compared to the consensus estimate of $10.44 million. During the same period last year, the company earned ($1.78) EPS. Sell-side analysts predict that Sutro Biopharma will post -2.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in STRO. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Sutro Biopharma during the 4th quarter worth $26,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Sutro Biopharma in the 4th quarter valued at about $32,000. Virtu Financial LLC purchased a new position in shares of Sutro Biopharma in the 3rd quarter worth approximately $77,000. Vontobel Holding Ltd. raised its stake in shares of Sutro Biopharma by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after acquiring an additional 10,000 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in Sutro Biopharma by 74.3% during the fourth quarter. ProShare Advisors LLC now owns 26,961 shares of the company’s stock valued at $50,000 after acquiring an additional 11,494 shares during the last quarter. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.